Investor Relations Home
|Recent Press Releases||More >>|
|07/02/14||Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program|
|CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).
"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance these drugs and add additional new drugs to our pipeline with GSK,"... |
|06/24/14||Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx|
|CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripher... |
|06/17/14||Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec|
|CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in an... |
|06/16/14||Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes|
|Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing
Treated patients achieved statistically significant reductions in measures of glucose control
Isis to host an investor event and live webcast at 6:30 a.m. PDT on Monday, June 16 in San Francisco
CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on... |
|D. Wade Walke, Ph.D.|
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
For more information requests, please visit our Information Request page.
If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.